OBJECTIVES: To determine the positive recommendation rate for combination drugs under the CDR.  METHODS: In Canada, eligible non-cancer prescription drugs approved by Health Canada (including combination drugs) are reviewed by the Common Drug Review (CDR) process that is part of the Canadian Agency for Drugs and Technologies in Health (CADTH). The CDR makes reimbursement recommendations that are considered by provincial and federal plans in making their formulary coverage decisions. The majority of the combination drugs consist of individual components that are currently available in the market. The advantages to combination drugs are several, including reduced dispensing fees, reduced pill burden and possibly synergistic effect.  CDR-reviewed combination drugs in our proprietary CDR Tracker^®database were analyzed. RESULTS: CONCLUSIONS: The high positive recommendation rate for combination drugs may be reflective of the various clinical and economic advantages of this drug class.